APPLICATION OF TICAGRELOR OR CLOPIDOGREL BASED DUAL ANTIPLATELET THERAPY FOLLOWING A PHARMACOINVASIVE STRATEGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE VITAL HEART RESPONSE REGISTRY

Ticagrelor (TIC) based dual antiplatelet therapy (DAPT) is standard of care for acute coronary syndromes (ACS) with the exception of fibrinolysis treated ST-segment elevation myocardial infarction (STEMI) patients where clopidogrel (CLOP) is recommended. Although comparable 30-day safety was shown